165 related articles for article (PubMed ID: 26606912)
21. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Ghosh A; Gupta R; Misra A
J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
[No Abstract] [Full Text] [Related]
22. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
[No Abstract] [Full Text] [Related]
23. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
Zechmann S
Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
[No Abstract] [Full Text] [Related]
24. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
[TBL] [Abstract][Full Text] [Related]
25. SGLT2 inhibitors for primary prevention of cardiovascular events.
Raz I; Cernea S; Cahn A
J Diabetes; 2020 Jan; 12(1):5-7. PubMed ID: 31755238
[No Abstract] [Full Text] [Related]
26. SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms.
Filippatos TD; Tsimihodimos V; Liamis G; Elisaf MS
Diabetes Metab Syndr; 2018; 12(1):59-63. PubMed ID: 28826578
[TBL] [Abstract][Full Text] [Related]
27. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
[TBL] [Abstract][Full Text] [Related]
28. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
29. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Bloch MJ
J Am Soc Hypertens; 2016 Mar; 10(3):186-7. PubMed ID: 27408945
[No Abstract] [Full Text] [Related]
30. Results from Cardiovascular Outcome Trials in Diabetes.
Muñoz Torres M; Muñoz Garach A
Endocrinol Nutr; 2016; 63(7):317-9. PubMed ID: 27324936
[No Abstract] [Full Text] [Related]
31. Unraveling the association of heart failure from drug and disease: Insights from recent cardiovascular trials in type 2 diabetes mellitus.
Peters MN; Pollock JS; Rajagopalan S
J Diabetes Complications; 2016 Mar; 30(2):189-91. PubMed ID: 26632087
[No Abstract] [Full Text] [Related]
32. Empagliflozin: A Review in Type 2 Diabetes.
Frampton JE
Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
[TBL] [Abstract][Full Text] [Related]
33. Canagliflozin: a new drug for type 2.
Goldman-Levine J
Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
[No Abstract] [Full Text] [Related]
34. SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Rajput R; Ved J
Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S433-S438. PubMed ID: 28395977
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
36. [The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Rupprecht H
MMW Fortschr Med; 2015 Jan; 157(1):55-8. PubMed ID: 25743304
[No Abstract] [Full Text] [Related]
37. [Novel therapeutic options in patients with type 2 diabetes and high cardiovascular risk].
Laubner K; Seufert J
Dtsch Med Wochenschr; 2016 Jun; 141(11):757-60. PubMed ID: 27176455
[TBL] [Abstract][Full Text] [Related]
38. Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
McReelis KD; Lovshin JA
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S4-S7. PubMed ID: 29074013
[No Abstract] [Full Text] [Related]
39. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
40. Increased grip strength with sodium-glucose cotransporter 2.
Sano M; Meguro S; Kawai T; Suzuki Y
J Diabetes; 2016 Sep; 8(5):736-7. PubMed ID: 27038414
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
